High-dose versus low-dose haemofiltration for the treatment of critically ill patients with acute kidney injury: an updated systematic review and meta-analysis

Peng Li,¹ Li-ping Qu,² Dong Qi,¹ Bo Shen,³,⁴ Yi-mei Wang,³,⁴ Jia-rui Xu,³,⁴ Wu-hua Jiang,³,⁴ Hao Zhang,³,⁴ Xiao-qiang Ding,³,⁴,⁵ Jie Teng³,⁴,⁵

To cite: Li P, Qu L, Qi D, et al. High-dose versus low-dose haemofiltration for the treatment of critically ill patients with acute kidney injury: an updated systematic review and meta-analysis. BMJ Open 2017;7:e014171. doi:10.1136/bmjopen-2016-014171

ABSTRACT

Objective The purpose of this study was to perform a systematic review and meta-analysis to evaluate the effect of high-dose versus low-dose haemofiltration on the survival of critically ill patients with acute kidney injury (AKI). We hypothesised that high-dose treatments are not associated with a higher risk of mortality.

Design Meta-analysis.

Setting Randomised controlled trials and two-arm prospective and retrospective studies were included.

Participants Critically ill patients with AKI.

Interventions Continuous renal replacement therapy.

Primary and secondary outcome measures Primary outcomes: 90-day mortality, intensive care unit (ICU) mortality, hospital mortality; secondary outcomes: length of ICU and hospital stay.

Result Eight studies including 2970 patients were included in the analysis. Pooled results sh owed no significant difference in the 90-mortality rate between patients treated with high-dose or low-dose haemofiltration (pooled OR=0.90, 95% CI 0.73 to 1.11, p=0.32). Findings were similar for ICU (pooled OR=1.12, 95% CI 0.94 to 1.34, p=0.21) and hospital mortality (pooled OR=1.03, 95% CI 0.81 to 1.30, p=0.84). Length of ICU and hospital stay were similar between high-dose and low-dose groups. Pooled results are not overly influenced by any one study, different cut-off points of prescribed dose or different cut-off points of delivered dose. Meta-regression analysis indicated that the results were not affected by the percentage of patients with sepsis or septic shock.

Conclusion High-dose and low-dose haemofiltration produce similar outcomes with respect to mortality and length of ICU and hospital stay in critically ill patients with AKI. This study was not registered at the time the data were collected and analysed. It has since been registered on 17 February 2017 at http://www.researchregistry.com/, registration number: reviewregistry211.

INTRODUCTION

Acute kidney injury (AKI) occurs in at least 5% of patients with who are admitted to the intensive care unit (ICU) and is an independent predictor of mortality.1–3 In addition, about 50% of patients with septic shock will experience AKI.4 The prognosis of patients with AKI is low, with a mortality rate of up to 70% despite improvements in haemodialysis and availability.5–7

Two methods for obtaining clearance in patients with AKI who require renal support are haemofiltration and haemodialysis. Haemofiltration uses convection to aid in the removal of middle molecular weight solutes, which is determined by the pore size of the membrane.8 Haemofiltration is believed to be superior to haemodialysis in patients with AKI as it is thought it can remove the toxic mediators of sepsis and inflammation.8

For patients who require renal replacement therapy (RRT), the treatment dose or intensity may influence outcomes. Continuous renal replacement therapy (CRRT) in the form of haemofiltration is an option for treating patients with AKI and may provide better clearance of toxic molecules, acid–base homeostasis and removal of inflammatory mediators that can contribute to organ injury and dysfunction than other methods.9–13
not clear. Some studies have reported benefits with intensive doses of CRRT with respect to mortality, while others have not. Several prior systematic reviews and meta-analyses have assessed the use of CRRT for treating AKI. These studies found that high-dose CRRT was not associated with a decrease in mortality in patients with AKI. Since the publication of these reviews, additional clinical studies have been published that addressed the use of CRRT in AKI. Prior reviews have addressed both haemofiltration and haemodialysis, which may not provide sufficient data with respect to either method.

Thus, the purpose of this study was to perform a systematic review and meta-analysis to evaluate the effect of high-dose versus low-dose haemofiltration on the survival of critically ill patients with AKI. We hypothesised that high-dose treatments are not associated with a higher risk of mortality.

MATERIALS AND METHODS

Search strategy
This meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. This study was not registered at the time the data were collected and analysed. It has since been registered on 17 February 2017 at http://www.researchregistry.com/, registration number: reviewreg211.

PubMed, Medline, Cochrane and Google Scholar databases were searched until 22 June 2016 using the following search terms: renal replacement therapy, renal dialysis, acute kidney injury, intensive care unit, intensity and dose. Included studies were randomised controlled trials (RCTs), two-arm prospective, retrospective or cohort studies that evaluated critically ill patients with AKI who received haemofiltration. Included studies had to report quantitative outcomes of interest. Letters, comments, editorials, case reports, proceedings and personal communications were excluded. Studies that evaluated patients who had received previous RRT during the same hospital admission or who were on maintenance dialysis for end-stage kidney disease were excluded. The database searches were performed by two independent (two of the authors) reviewers. The authors independently reviewed all potential studies and extracted data of interest. A third reviewer was consulted to resolve any questions regarding inclusion of studies or data in the analysis, and a decision was arrived at by consensus.

Data extraction and quality assessment
The following information/data were extracted from studies that met the inclusion criteria: the name of the first author, year of publication, study design, number of participants in each group, participants’ age and gender and the major outcomes of death up to 90 days (90-day mortality), ICU mortality, hospital mortality and length of hospital or ICU stay.

The quality of the included studies was evaluated using the Cochran Risk of Bias tool outlined in the Cochrane Collaboration Handbook for Systematic Reviews of Interventions V.5.1.0.25

Statistical analysis
Primary outcomes were 90-day mortality, ICU mortality and hospital mortality. Secondary outcomes were length of ICU and hospital stay. Comparisons of the different mortality rates between patients receiving high-dose or low-dose haemofiltration were presented by OR and 95% CI; an OR >1 indicated that patients treated with high-intensity haemofiltration had a higher risk of death. The effect size of length of ICU and hospital stay was reported as difference in means; a difference in means >0 indicated longer ICU or hospital stay in patients treated with high-dose haemofiltration. Pooled estimates for ORs and difference in means were calculated using the DerSimonian and Laird random-effects model. A two-sided p value <0.05 was considered statistically significant.

Heterogeneity was assessed using the Cochran Q and the I² statistic. For the Q statistic, p<0.10 was considered statistically significant for heterogeneity. The I² statistic indicates the percentage of the observed between-study variability due to heterogeneity. The suggested ranges are as follows: no heterogeneity (I²=0% to 25%), moderate heterogeneity (I²=25% to 50%), large heterogeneity (I²=50% to 75%) and extreme heterogeneity (I²=75% to 100%).

Sensitivity analysis was performed for the primary outcomes using the leave-one-out approach. Due to various definitions of high-dose and low-dose haemofiltration between the studies, additional sensitivity analysis was performed to examine the stability of pooled estimates according to various cut-off points of prescribed dose as well as the actual delivered dose. Meta-regression analysis was performed to examine whether the percentage of patients with sepsis or septic shock influenced the pooled estimates of the associations between haemofiltration and outcomes of interest. All analyses were performed using Comprehensive Meta-Analysis statistical software, V.2.0 (Biostat, Englewood, New Jersey, USA).

RESULTS
A total of 374 studies were identified in the initial search, of which 250 were excluded for being duplicate publications (figure 1). Of the remaining 124 studies, 106 were excluded for not being relevant by review of title and/or abstract. The remaining 18 full-text articles were examined, and 10 were excluded, the reasons for which are shown in figure 1. Thus, eight studies were included in the meta-analysis.

Of the eight studies, seven were RCTs and one was a prospective study (table 1). A total of 2970 patients were included, and the number of patients per study ranged from 19 to 1465. The mean patient age ranged from 59 to 73 years, over half of the patients
were male (54% to 80%), and the causes for of AKI requiring RRT were sepsis, surgery (including cardiovascular surgery) and septic shock. Six of the eight studies reported mean Acute Physiology and Chronic Health Evaluation (APACHE) II or III scores for the groups studied, and the mean scores were similar between the groups in the individual studies. The type of treatment and the definition of high-dose or more-intensive therapy varied across the studies. The doses used also varied, with low-dose ranging from 20 to 36 mL/kg/h and high-dose ranging from 35 to 85 mL/kg/h.

Meta-analysis

Results of meta-analysis of the primary outcomes of within 90-day mortality, ICU mortality, and hospital mortality are presented in figure 2. The pooled results showed no significant difference in the 90-mortality rate between patients treated with high-dose or low-dose haemofiltration (pooled OR=0.90, 95% CI 0.73 to 1.11, p=0.32) (figure 2A). The findings were similar for ICU mortality (pooled OR=1.12, 95% CI 0.94 to 1.34, p=0.21) and hospital mortality (pooled OR=1.02, 95% CI 0.81 to 1.30, p=0.84) (figure 2B, C). There was low to moderate heterogeneity across the studies for each outcome (Q=4.10, p=0.25, I²=26.7%; Q=2.24, p=0.52, I²=0%; and Q=1.49, p=0.69, I²=0%, respectively).

No significant difference was found in the length of ICU stay between patients who received high- versus low-dose treatment (pooled difference in means=−2.09, 95% CI −5.64 to 1.45, p=0.25) (figure 2D). However, large heterogeneity was observed across the seven studies that reported data for length of ICU stay (Q=25.10, p<0.001, I²=76.1%). The results were similar for length of hospital stay (pooled difference in means=−0.03, 95% CI −2.38 to 2.31, p=0.98); however, no heterogeneity was observed for data regarding length of hospital stay (Q=1.74, p=0.78, I²=0%) (figure 2E).

Sensitivity analysis, meta-regression analysis and quality assessment

Sensitivity analysis was performed in several ways. First, we used the leave-one-out approach to examine whether any single study influenced the pooled results of primary outcomes. The pooled results for the three primary outcomes did not significantly change when each study was removed in turn (figure 3). Second, the use of various cut-off points of prescribed dose might minimise the influence of the various definitions of high-dose and low-dose in the included studies. Analysis indicated that the results were stable regardless of cut-off points of prescribed dose. Furthermore, we also performed analyses for the actual delivered dose with the same cut-off points, and the
Table 1  Summary of basic characteristics of studies included in the meta-analysis

| Study                | Study design | Number of patients | Treatment          | Prescribed dose (mL/kg/h) | Delivered dose (mL/kg/h) | Duration (d) | Age (year) | Male (%) | Major cause of AKI | Mean APACHE II score |
|----------------------|--------------|--------------------|--------------------|--------------------------|--------------------------|---------------|-------------|----------|-------------------|----------------------|
| Joannes-Boyau et al  | RCT          | 66                 | High-volume HF    | 70                       | 65.6 (40–67.9)*          | 96 hours      | 68 (58–77)* | 68.0     | Sepsis            | 66 (100%)            |
|                      |              | 71                 | Standard-volume HF| 35                       | 33.2 (28.7–33.6)*        | 70 (58–75)* | 54.0        | 71 (100%)|
| Vesconi et al        | Prospective  | 75                 | More intensive    | 35                       | 44.8 (9.4)               | 2 (1–3)*      | 61.01 (15.9) | 58.1     | Surgery           | 33 (40.5%) 36 (48.6%) |
|                      |              | 202                | Less intensive    | 21–34                    | 26.9 (4.0)               | 4 (2–8)*      | 63.48 (15.9) | 67.8     | 81 (40.1%)        | 84 (41.7%)            |
|                      |              | 61                 | Less intensive    | 20                       | 15.4 (4.2)               | 3 (2–6)*      | 59.05 (19.0) | 73.8     | 19 (31.2%)        | 30 (49.5%)            |
| Zhang et al          | RCT          | 141                | EHVHF             | 85                       | 87.54 (12.54)            | 9.38 (12.06)  | 56.62 (16.38) | 58.9     | Septic shock      | 72 (51.06%) 21.97     |
|                      |              | 139                | HVHF              | 50                       | 49.99 (9.65)             | 8.88 (10.79)  | 59.96 (18.81) | 64.0     | 69 (49.64%)       | 22.6                 |
| Bouman et al         | RCT          | 35                 | EHV               | 72                       | 48.2 (42.3–58.7)*        | 68.5 (28.0–140.8)* | 68 (13)  | 60.0     | 35 (100%)        | 23.5                 |
|                      |              | 35                 | ELV               | 24–36                    | 20.1 (17.5–22.0)*        | 94.0 (53.0–181.5)* | 70 (10)  | 57.0     | 35 (100%)        | 21.7                 |
|                      |              | 36                 | LLV               | 24–36                    | 19.0 (16.6–21.2)*        | 69.5 (28.3–157.7)* | 67 (13)  | 61.0     | 30 (100%)        | 23.6                 |
| Tolwani et al        | RCT          | 100                | High dosage       | 35                       | 29                       | 10.0 (9.8)   | 58 (16)     | 59.0     | Septic shock      | 54 (54%) 64 (64%)     |
|                      |              | 100                | Standard dosage   | 20                       | 17                       | 9.7 (1.3)    | 62 (15)     | 57.0     | 54 (54%)          | 63 (63%)              |
|                      |              |                    |                    |                          |                          |              |             |          |                  | 26                   |
| Bellomo (2009)       | RCT          | 722                | Higher-Intensity CRRT | 40                     | 33.4 (12.8)             | 6.3 (8.7)    | 64.7 (14.5) | 65.7     | Sepsis           | 360 (49.9) 430 (59.6%) 102.5 |
|                      |              | 743                | Lower-Intensity CRRT | 25                     | 22 (17.8)               | 5.9 (7.7)    | 64.4 (15.3) | 63.5     | 363 (48.9)        | 444 (59.8%) 102.3 |
| Boussekey et al      | RCT          | 9                  | HVHF              | 65                       | 62                       | 7 (2–17)*    | 68 (58–74)* | 78.0     | Sepsis           | 9 (100%) 31           |
|                      |              | 10                 | LVHF              | 35                       | 32                       | 6 (2–14)*    | 72.5 (54–77)* | 80.0     |                  | 10 (100%) 33.5       |
| Ronco et al          | RCT          | 146                |                   | 20                       | 61 (10)                  | 55.5         |             |          | Surgery           | 20 (14%) 22            |
|                      |              | 139                |                   | 35                       | 59 (9)                   | 55.4         |             |          |                  | 17 (12%) 24           |
|                      |              | 140                |                   | 45                       | 63 (12)                  | 57.1         |             |          |                  | 15 (11%) 22           |

*Data were presented by median and IQR and by mean and SD if not specified.
†Measured by APACHE III.
‡Numbers were shown in hours.
AKI, acute kidney injury; CRRT, continuous renal-replacement therapy; EHV, early high-volume haemofiltration; EHVHF, extra high-volume haemofiltration; ELV, early low-volume haemofiltration; HF, haemofiltration; HVHF, high-volume haemofiltration; LLV, late low-volume haemofiltration; LVHF, low-volume haemofiltration; RCT, randomised controlled trial.
Li P, et al. BMJ Open 2017;7:e014171. doi:10.1136/bmjopen-2016-014171

Figure 2  Meta-analysis for treatment effect of haemofiltration on (A) mortality within 90 days, (B) ICU mortality, (C) in hospital mortality, (D) length of ICU stay and (E) length of hospital stay. ICU, intensive care unit.

Figure 3  Sensitivity analysis using leave-one-out approach for the treatment effect of haemofiltration (A) mortality within 90 days, (B) ICU mortality and (C) in hospital mortality.

statistical significance was consistent when delivered dose was used in the analysis (table 2). Taken together, these findings indicate that the pooled results are not overly influenced by any one study, different cut-off points of prescribed dose or different cut-off points of delivered dose.

Meta-regression analysis was performed to examine whether patients with sepsis or septic shock affected the overall pooled analysis. The reason for the analysis was based on the fact that sepsis and septic shock differ in terms of blood pressure instability and possible emergent death. The results showed that the regression coefficients had a slope close to 0, indicating that the associations between RRT and selected outcomes were not influenced by the percentage of patients with sepsis or septic shock (p values for all slope coefficients >0.05) (table 3).

Assessment of the quality of the included studies using the Cochran Risk of Bias tool indicated that there was low risk of bias for most of the studies (Figure S1A and S1B). One exception was the study of Vesconi et al,27 which showed a high risk of selection, performance and detection bias (Figure S1B). Overall, the included studies were of adequate quality.

Publication bias assessment was not performed due to limited number of included studies; 10 or more studies are necessary to assess publication bias.28

DISCUSSION

The purpose of this study was to conduct a systematic review and meta-analysis to examine the effect of haemofiltration dosage on mortality, length of hospital stay, and length of ICU stay in patients with AKI. For all outcomes examined, there was no difference between patients who received high- versus low-dose haemofiltration. The results were consistent when the analyses used prescribed or delivered dose, and not influenced by the percentage of patients with sepsis or septic shock. Sensitivity analysis and quality assessment indicated no one study dominated the results, and that the included data were of adequate quality.

The results of this study are consistent with three prior meta-analyses, all of which found no survival benefit, or increased mortality, of high-dose CRRT in patients with
Table 2  | Sensitivity analysis for treatment effect on mortality according to different cut-off points of prescribed dose and delivered dose

| Number of studies included | Prescribed dose | Pooled OR | Lower limit | Upper limit | Z value | p Value |
|----------------------------|-----------------|-----------|-------------|-------------|---------|---------|
| (A) 90-day mortality       |                 |           |             |             |         |         |
| 50 mL/kg/h                 | 2               | 0.97      | 0.66        | 1.43        | −0.16   | 0.88    |
| 40 mL/kg/h                 | 3               | 0.83      | 0.50        | 1.38        | −0.71   | 0.48    |
| 30 mL/kg/h                 | 2               | 0.73      | 0.39        | 1.38        | −0.97   | 0.33    |
| (B) ICU mortality          |                 |           |             |             |         |         |
| 50 mL/kg/h                 | 1               | 1.20      | 0.58        | 2.47        | 0.50    | 0.62    |
| 40 mL/kg/h                 | 2               | 1.04      | 0.85        | 1.28        | 0.37    | 0.72    |
| 30 mL/kg/h                 | 3               | 1.13      | 0.92        | 1.38        | 1.18    | 0.24    |
| (C) Hospital mortality     |                 |           |             |             |         |         |
| 50 mL/kg/h                 | 2               | 1.11      | 0.75        | 1.65        | 0.53    | 0.60    |
| 40 mL/kg/h                 | 2               | 1.02      | 0.71        | 1.45        | 0.08    | 0.94    |
| 30 mL/kg/h                 | 2               | 0.98      | 0.73        | 1.31        | −0.15   | 0.88    |

Delivered dose

| Number of studies included | Delivered dose | Pooled OR | Lower limit | Upper limit | Z value | p Value |
|----------------------------|---------------|-----------|-------------|-------------|---------|---------|
| (A) 90-day mortality       |               |           |             |             |         |         |
| 50 mL/kg/h                 | 2             | 0.97      | 0.66        | 1.43        | −0.16   | 0.88    |
| 40 mL/kg/h                 | 1             | 1.24      | 0.63        | 2.43        | 0.63    | 0.53    |
| 30 mL/kg/h*                | 1             | 1.00      | 0.81        | 1.23        | −0.03   | 0.97    |
| (B) ICU mortality          |               |           |             |             |         |         |
| 50 mL/kg/h                 | 1             | 1.20      | 0.58        | 2.47        | 0.50    | 0.62    |
| 40 mL/kg/h                 | 2             | 1.39      | 0.96        | 2.00        | 1.75    | 0.08    |
| 30 mL/kg/h                 | 2             | 1.16      | 0.84        | 1.62        | 0.90    | 0.37    |
| (C) Hospital mortality     |               |           |             |             |         |         |
| 50 mL/kg/h                 | 1             | 0.99      | 0.61        | 1.61        | −0.03   | 0.98    |
| 40 mL/kg/h                 | 1             | 1.39      | 0.71        | 2.74        | 0.96    | 0.34    |
| 30 mL/kg/h                 | 1             | 0.91      | 0.65        | 1.29        | −0.52   | 0.60    |

*Ronco et al.14 did not provide information on delivered dose of continuous renal replacement therapy and therefore was excluded.

ICU, intensive care unit.

Table 3  | Meta-regression analysis for each outcome

| Outcome                  | Intercept* | Slope* |
|--------------------------|------------|--------|
| Mortality within 90 days | −0.42 (0.19) | 0.01 (0.004) |
| ICU mortality            | 0.31 (0.35) | −0.004 (0.01) |
| Hospital mortality       | 0.31 (0.34) | −0.01 (0.01) |
| Length of ICU stay       | −2.89 (1.90) | 0.03 (0.04) |
| Length of hospital stay  | −1.74 (4.13) | 0.034 (0.08) |

*Presented as point estimate of coefficient and SE.

ICU, intensive care unit.

Although, our findings are similar to prior studies, a strength of our analysis is the meta-regression analysis with evaluated the impact of patients with sepsis or septic shock on the overall pooled analysis. The meta-regression analysis indicated that heterogeneity due to a mixed population of sepsis and septic shock patients did not influence the pooled results. In addition, we included two additional studies that were not included in the prior meta-analyses. The consistency of finding across the different meta-analyses, and findings of our meta-regression analysis, suggest that the delivered dose is not affected by the presence of systemic infection, and any variance seen when treating patients may reflect the severity of the acute kidney disease and/or an individual patient’s condition.

The data from clinical studies on the benefit of high-dose haemofiltration in critically ill patients have been inconsistent. In 2000, Ronco et al.14 reported improved survival with higher total effluent volumes (>45 mL/kg/h) in patients with septic AKI, and in 2008, in a small pilot study, Boussekey et al.26 found that high-dose RRT was associated with an improved haemodynamic profile. However, that study did not find any significant effect on survival or organ dysfunction. In contrast, two
randomised controlled multicentre studies found no added survival benefit of high-dose compared with standard-dose CRRT in critically ill patients with AKI. A more recent study by Joannes-Boyau et al also found no evidence that high-dose (70 mL/kg/h) compared with standard-dose (35 mL/kg/h) RRT resulted in reduction in 28-day mortality, or to early improvements in haemodynamic profile or organ dysfunction in septic shock patients with AKI.

A prior meta-analysis compared the efficacy of extended daily dialysis (EDD) and CRRT in treating patients with AKI. Zhang et al included 17 studies from 2000 to 2014 with a total of 1208 patients. Meta-analysis of the included RCTs (n=10) found no difference in mortality rates between EDD and CRRT (relative risk, 0.90; 95% CI 0.74 to 1.11; p=0.3). However, lower mortality risk was observed with EDD compared with CRRT in observational studies (relative risk, 0.86; 95% CI 0.74 to 1.00; p=0.05). For both RCTs and observational studies, recovery of kidney function, fluid removal and days in the ICU were similar between procedures. The authors concluded that the findings from RCTs suggest that CRRT and EDD have similar efficacy and that the difference in mortality observed in the analysis of the observational studies may be confounded by selection bias. The potential confounding effect of observational studies is also indicated by our quality assessment of the included studies that indicated that the observational study of Vesconi et al had a high risk of selection bias, as well as performance and detection bias.

The current analysis focused on haemofiltration. However, haemodialysis is also used to treat patients with AKI. Friedrich et al performed a meta-analysis in 2012 that included 19 RCTs that focused on the difference between haemofiltration and haemodialysis with similar doses. They found weak evidence supporting the increased clearance of medium to large molecules by haemofiltration compared with haemodialysis, but there was no difference in mortality between the two methods. No dose comparison was performed in their study.

Our study was limited by the considerable variation across the studies with regard to the prescribed doses for high-dose and low-dose haemofiltration. It is difficult to standardise the prescribed and delivered doses across the studies due to differences in equipment used and personnel. There was also a wide range of effect size, and several of the studies reported opposite findings. In addition, only four of the included studies reported data for the primary endpoint of mortality within 90 days, and not all the studies were RCTs. In addition, due to the heterogeneity of dosing across studies, the differences in the definition of high-dose, and the fact that the raw data for each group was not presented, it was difficult to group the analysis according to a cut-off value of the standard of care dose of 35 mL/kg/h. For example, Vesconi et al defined 35 mL/kg/h as ‘more intensive’ and compared the finding of that dosing with ‘less intensive’ <20 to 34 mL/kg/h. This differed, for example, from the study by Zhang et al, which compared 85 mL/kg/h with 50 mL/kg/h. It is highly possible that this variability may have confounded our results. However, sensitivity analysis found that no one study overly influences the findings; thus, suggesting that although heterogeneity in dosing was present, the pooled results are robust. In addition, six of the eight studies reported mean APACHE II or III scores for the groups studied, and the mean scores were similar between the groups in the individual studies, indicating that the illness severity was similar between the groups in each of these six studies. Subgroup analyses of different covariates, such as according to renal function, would aid in the analysis; however, due to limited availability of raw data, few variables can be investigated. Lastly, our original intention was to perform a meta-analysis examining the outcomes of using different doses of RRT, and during our initial literature search, we included all modalities of CRRT. However, we found that the majority of studies that compared different dosages used haemofiltration rather than other modalities. For this reason, we limited the analysis to haemofiltration.

The results of this meta-analysis found that mortality rates and length of ICU and hospital stay were not different between critically ill patients with AKI who received high-dose or low-dose haemofiltration.

Acknowledgements We would like to express our sincere gratitude to our colleagues whose names did not appear as authors but also contributed to the study. We especially thank Xiao Tan, Jifu Jin and Zhouping Zou for collecting the data.

Contributors PL: study design; literature research; manuscript preparation. LQ: study design, literature research and manuscript preparation. DG: manuscript preparation, data acquisition and data analysis. BS: manuscript preparation, data acquisition and data analysis. JW: manuscript preparation, data acquisition and data analysis. XJ: manuscript preparation, data acquisition and data analysis. WJ: data analysis and statistical analysis. HZ: data analysis and statistical analysis. XD: guarantor of integrity of the entire study and study concepts. JT: study concepts, study design, guarantor of integrity of the entire study and manuscript editing.

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

1. Metnitz PG, Krenn CG, Steltzer H, et al. Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med 2002;30:2051–8.
2. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005;294:813–8.
3. Uchino S, Bellomo R, Goldsmith D, et al. An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. Crit Care Med 2006;34:1913–7.
4. Bagshaw SM, Uchino S, Bellomo R, et al. Timing of renal replacement therapy and clinical outcomes in critically ill patients with severe acute kidney injury. J Crit Care 2009;24:129–40.
5. Keir I, Kellum JA. Acute kidney injury in severe sepsis: pathophysiology, diagnosis, and treatment recommendations. *J Vet Emerg Crit Care* 2015;25:200–9.

6. Kellum JA, Angus DC. Patients are dying of acute renal failure. *Crit Care Med* 2002;30:2156–7.

7. Srisawat N, Kellum JA. Acute kidney injury: definition, epidemiology, and outcome. *Curr Opin Crit Care* 2011;17:548–55.

8. Depner TA. “Artificial” hemodialysis versus “natural” hemofiltration. *Am J Kidney Dis* 2008;52:403–6.

9. Bellomo R, Tipping P, Boyce N. Continuous veno-venous hemofiltration with Dialysis removes cytokines from the circulation of septic patients. *Crit Care Med* 1993;21:522–6.

10. Heering P, Morgera S, Schmitz FJ. Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration. *Intensive Care Med* 1997;23:288–96.

11. Hoffmann JN, Hartl WH, Deppisch R, et al. Effect of hemofiltration on hemodynamics and systemic concentrations of anaphylatoxins and cytokines in human sepsis. *Intensive Care Med* 1996;22:1360–7.

12. Honore PM, Joannes-Boyau O. High-dose renal replacement therapy in critically ill patients with acute kidney injury: a single-center randomized clinical trial. *Nephrol Dial Transplant* 2012;27:967–73.

13. Rimméle T, Kellum JA. High-volume hemofiltration in the intensive care unit: a blood purification therapy. *Anesthesiology* 2012;116:1377–87.

14. Ronco C, Bellomo R, Hornel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. *Lancet* 2000;356:26–30.

15. Saudan P, Niederberger M, De Seigneur S, et al. Adding a Dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. *Kidney Int* 2006;70:1312–7.

16. Bouman CS, Oudemans-Van Straaten HM, Tijssen JG, et al. Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. *Crit Care Med* 2002;30:2205–11.

17. Bellomo R, Cass A, Cole L, et al. Intensity of continuous renal-replacement therapy in critically ill patients. *N Engl J Med* 2009;361:1627–38.

18. Palevsky PM, Zhang JH, O’Connor TZ, et al. VA/NIH Acute Renal Failure Trial Network. Intensity of renal support in critically ill patients with acute kidney injury. *N Engl J Med* 2008;359:7–20.

19. Tolwani AJ, Campbell RC, Stefan BS, et al. Standard versus high-dose CVVHDF for ICU-related acute renal failure. *J Am Soc Nephrol* 2008;19:1233–8.

20. Casey ET, Gupta BP, Erwin PJ, et al. The dose of continuous renal replacement therapy for acute renal failure: a systematic review and meta-analysis. *Ren Fail* 2010;32:555–61.

21. Negash DT, Ohingra VK, Copland M, et al. Intensity of continuous renal replacement therapy in acute kidney injury in the intensive care unit: a systematic review and meta-analysis. *Vasc Endovascular Surg* 2011;45:504–10.

22. Van Wirt R, Friedrich JO, Scales DC, et al. High-dose renal replacement therapy for acute kidney injury: systematic review and meta-analysis. *Crit Care Med* 2010;38:1360–9.

23. Joannes-Boyau O, Honore PM, Perez P, et al. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVORE study): a multicentre randomized controlled trial. *Intensive Care Med* 2013;39:1535–46.

24. Zhang P, Yang Y, Lv R, et al. Effect of the intensity of continuous renal replacement therapy in patients with Sepsis and acute kidney injury: a single-center randomized clinical trial. *Nephrol Dial Transplant* 2012;27:967–73.

25. Higgin JPT. Cochrane collaboration handbook for systematic reviews of interventions Version 5.1.0. Cochrane Collab 2011. www.cochrane-handbook.org

26. Boussekey N, Chiche A, Faure K, et al. A pilot randomized study comparing high and low volume hemofiltration on vasopressor use in septic shock. *Intensive Care Med* 2008;34:1646–53.

27. Vesconi S, Cruz DN, Fumagalli R, et al. Delivered dose of renal replacement therapy and mortality in critically ill patients with acute kidney injury. *Crit Care* 2009;13:R57.

28. Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ* 2011;343:d4002.

29. Zhang L, Yang J, Eastwood GM, et al. Extended daily dialysis versus continuous renal replacement therapy for acute kidney injury: a meta-analysis. *Am J Kidney Dis* 2015;66:322–30.

30. Friedrich JO, Wald R, Bagshaw SM, et al. Hemofiltration compared to hemodialysis for acute kidney injury: systematic review and meta-analysis. *Crit Care* 2012;16:R146.